Korean J Gastroenterol.  2014 Feb;63(2):82-89. 10.4166/kjg.2014.63.2.82.

Trends in the Eradication Rates of Helicobacter pylori Infection in Daegu and Gyeongsangbuk-do, Korea: Multicenter Study over 13 Years

• Jung YS
• Lee SH
• Park CS
• Oh MJ
• Kim KO
• Jang BI
• Jeon SW
• Jung MK
• Park KS
• Kim ES
• Cho KB
• Jung JT
• Kwon JG
• Kim EY
• Kim WJ
• Yang CH

• KMID: 1730914
• DOI: http://doi.org/10.4166/kjg.2014.63.2.82

Abstract

BACKGROUND/AIMS
The eradication rates of Helicobacter pylori infection have been reported to have decreased over the years due to antibiotics resistance. The aim of this study is to investigate the trend of eradication rates of first-line triple therapy for H. pylori over the past 13 year period, and to evaluate factors affecting H. pylori eradication in Daegu and Gyeongsangbuk-do, Korea.
METHODS
A total of 2,982 patients with H. pylori infection who were treated with either 1 week or 2 weeks first-line therapy (proton pump inhibitor [PPI], amoxicillin, and clarithromycin) from January 1999 through December 2011 were included in this study. Data were collected by retrospectively reviewing the medical records.
RESULTS
The overall H. pylori eradication rate was 87.2%. The eradication rates from 1999 to 2011 fluctuated between 78.0% and 95.7%, but no definite evidence of a decreasing tendency was seen over the 13 year period (p=0.113). Furthermore, there was no significant difference in the eradication rate according to the duration of therapy (p=0.592). However, there was a significant difference in the eradication rate among various PPIs (p<0.01).
CONCLUSIONS
There was no decreasing trend in the H. pylori eradication rate over the past 13 years in Daegu and Gyeongsangbuk-do, Korea. There also was no difference in the eradication rates depending on duration of therapy. However, a significant difference was noted among various PPIs.

Keyword

Helicobacter pylori; Eradication

MeSH Terms

Adult
Aged
Amoxicillin/therapeutic use
Anti-Bacterial Agents/*therapeutic use
Clarithromycin/therapeutic use
Disease Eradication/*trends
Drug Administration Schedule
Drug Therapy, Combination
Endoscopy, Gastrointestinal
Esomeprazole/therapeutic use
Female
Helicobacter Infections/*drug therapy/pathology
*Helicobacter pylori
Humans
Logistic Models
Male
Middle Aged
Omeprazole/therapeutic use
Proton Pump Inhibitors/*therapeutic use
Rabeprazole/therapeutic use
Republic of Korea
Retrospective Studies
Treatment Outcome
Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Esomeprazole
Omeprazole
Proton Pump Inhibitors
Rabeprazole

Figure

• 

  Fig. 1. Trend of annual eradication rates (linear to linear association, p=0.113).

• 

  Fig. 2. Trend in the efficacy of 1 week vs. 2 weeks therapy for Helicobacter pylori eradication over the 13 year period (linear to linear association; 1 week p=0.310, 2 weeks p=0.147).

Reference

References

1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epi-thelium in active chronic gastritis. Lancet. 1983; 321:1273–1275.

2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1:1311–1315.

3. Blaser MJ. Helicobacter pylori and gastric diseases. BMJ. 1998; 316:1507–1510.

4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175–1186.

5. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92:1881–1888.

6. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011; 83:253–260.

7. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005; 100:2100–2115.

8. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001; 344:967–973.

9. Hunt RH, Xiao SD, Megraud F. World Gastroenterology Organization. World gastroenterology organisation global guideline: Helicobacter pylori in developing countries. J Dig Dis. 2011; 12:319–326.

10. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007; 12:333–340.

11. Korean Helicobacter pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol. 1998; 32:275–289.

12. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009; 54:269–278.

13. Kim SG, Jung HK, Lee HL, et al. Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol. 2013; 62:3–26.

14. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut. 1997; 41:735–739.

15. Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with non-ulcer dyspepsia. Clin Ther. 2008; 30:528–534.

16. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59:1143–1153.

17. Fujioka T, Aoyama N, Sakai K, et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol. 2012; 47:276–283.

18. Bang SY, Han DS, Eun CS, et al. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol. 2007; 50:356–362.

19. Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J Gastroenterol. 2004; 44:126–135.

20. Kim SY, Jung SW. Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol. 2011; 58:67–73.

21. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56:772–781.

22. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102:1808–1825.

23. Yamada T, Searle JG, Ahnen D. NIH Consensus development panel on Helicobacter pylori in peptic ulcer disease. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65–69.

24. Egan BJ, Katicic M, O'Connor HJ, O'Morain CA. Treatment of Helicobacter pylori. Helicobacter. 2007; 12(Suppl 1):31–37.

25. Byun YH, Jo YJ, Kim SC, et al. Clinical factors that predicts successful eradication of Helicobacter pylori. Korean J Gastroenterol. 2006; 48:172–179.

26. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002; 16(Suppl 1):24–30.

27. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut. 2012; 61:646–664.

28. Kim JY, Kim NY, Kim SJ, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol. 2011; 57:221–229.

29. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mu-tation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010; 44:536–543.

30. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004; 48:4843–4847.

31. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013; 18:206–214.

32. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol. 2006; 40:683–687.

33. Yoon JH, Baik GH, Sohn KM, et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol. 2012; 18:6628–6634.

34. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and re-infection rate after successful eradication. Korean J Gastroenterol. 2007; 50:170–175.

35. Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol. 2006; 48:156–161.

36. Song JG, Lee SW, Park JY. Trend in the eradication rates of Helicobacter pylori infection in the last 11 years. Korean J Med. 2009; 76:303–310.

37. Cho HJ, Bae RC, Lee SH, et al. The trend in the eradication rates of first- and second-line therapy for Helicobacter pylori infection in Daegu and Kyungpook provinces: a single center experience for the most recent 9 years. Korean J Med. 2009; 76:186–192.

38. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14:603–609.

39. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 147:553–562.

40. Sokwala A, Shah MV, Devani S, Yonga G. Helicobacter pylori eradication: a randomised comparative trial of 7-day versus 14-day triple therapy. S Afr Med J. 2012; 102:368–371.

41. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter. 2008; 13:542–549.

42. Paek NY, Lim YJ, Lee JH, Kang JH, Park JB, Lee JH. Recent eradication rates of first-line triple regimens for H. pylori infection. Korean J Gastrointest Endosc. 2010; 41:5–9.

43. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000; 14:963–978.

44. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol. 2004; 38:503–506.

45. Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether de-rivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000; 44:458–461.

46. Alarcón T, Domingo D, Sánchez I, Sanz JC, Martínez MJ, López-Brea M. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1998; 17:275–277.

47. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 18:647–654.

48. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003; 17:1237–1245.

49. Hong EJ, Park DI, Oh SJ, et al. Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors. Korean J Gastroenterol. 2008; 52:80–85.

50. Keum B, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol. 2005; 46:433–439.